Literature DB >> 5920657

Mefenamic acid and flufenamic acid compared with aspirin and phenylbutazone in rheumatoid arthritis.

D E Barnardo, H L Currey, R M Mason, W R Fox, M Weatherall.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5920657      PMCID: PMC1943158          DOI: 10.1136/bmj.2.5509.342

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  2 in total

1.  Evaluation of drug therapy in rheumatoid arthritis-study of flufenamic acid.

Authors:  E L COODLEY
Journal:  West Med Med J West       Date:  1963-07

2.  Anti-inflammatory, antipyretic and antinociceptive properties of N-(2,3-xylyl)anthranilic acid (mefenamic acid).

Authors:  C V WINDER; J WAX; L SCOTTI; R A SCHERRER; E M JONES; F W SHORT
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

  2 in total
  9 in total

1.  Mefenamic acid in rheumatoid arthritis.

Authors:  A B Myles; P A Bacon; K A Williams
Journal:  Ann Rheum Dis       Date:  1967-11       Impact factor: 19.103

Review 2.  Current therapy of rheumatoid arthritis.

Authors:  E J Kamin; C V Multz
Journal:  Calif Med       Date:  1969-01

3.  Mefenamic acid.

Authors: 
Journal:  Br Med J       Date:  1966-12-17

4.  Flufenamic acid in rheumatoid arthritis.

Authors:  K T Rajan; A G Hill; A Barr; E Whitwell
Journal:  Ann Rheum Dis       Date:  1967-01       Impact factor: 19.103

Review 5.  Antirheumatic drugs: clinical pharmacology and therapeutic use.

Authors:  G L Craig; W W Buchanan
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

6.  Assessment of drugs in out-patients with rheumatoid arthritis. Evaluation of methods and a comparison of mefenamic and flufenamic acids with phenylbutazone and aspirin.

Authors:  R M Mason; D E Barnardo; W R Fox; M Weatherall
Journal:  Ann Rheum Dis       Date:  1967-09       Impact factor: 19.103

7.  Autoimmune haemolytic anaemia and mefenamic acid therapy.

Authors:  G L Scott; A B Myles; P A Bacon
Journal:  Br Med J       Date:  1968-08-31

8.  Low concentration flufenamic acid enhances osteogenic differentiation of mesenchymal stem cells and suppresses bone loss by inhibition of the NF-κB signaling pathway.

Authors:  Xuenan Liu; Zheng Li; Hao Liu; Yuan Zhu; Dandan Xia; Siyi Wang; Ranli Gu; Weiliang Wu; Ping Zhang; Yunsong Liu; Yongsheng Zhou
Journal:  Stem Cell Res Ther       Date:  2019-07-19       Impact factor: 6.832

9.  Flufenamic Acid Inhibits Adipogenic Differentiation of Mesenchymal Stem Cells by Antagonizing the PI3K/AKT Signaling Pathway.

Authors:  Xuenan Liu; Zheng Li; Hao Liu; Yuan Zhu; Dandan Xia; Siyi Wang; Ranli Gu; Ping Zhang; Yunsong Liu; Yongsheng Zhou
Journal:  Stem Cells Int       Date:  2020-03-16       Impact factor: 5.443

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.